NeOnc Reports Additional Partial Response in Phase 2a Study of Intranasal NEO100

On November 17, 2026 NeOnc Technologies Holdings, Inc. (Nasdaq: NTHI) ("NeOnc" or the "Company"), a clinical-stage biopharmaceutical company developing therapies for central nervous system (CNS) cancers, reported updated interim results from the Phase 2a portion of NEO100-01, an open-label study of intranasal NEO100 in patients with recurrent or progressive Grade III or Grade IV IDH1-mutant glioma. One additional partial response brought the objective response rate to 12.5% (3 of 24 patients), compared with 8.3% (2 of 24 patients) in the August 12, 2026 topline results. Both rates were assessed using RANO 2.0 criteria.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

By RANO 2.0 criteria, three patients had a partial response (12.5%), 13 had stable disease (54.2%) and eight had progressive disease (33.3%). The disease control rate was 66.7%. Five patients remained on treatment at the interim database lock.

As previously reported, six-month progression-free survival, the study’s primary endpoint, was 48.9% (95% CI, 26.3%–68.1%) by RANO 2.0 using Kaplan–Meier estimation, compared with the prespecified 20% historical benchmark (one-sided p = 0.0047). Median overall survival was 26.1 months (95% CI, 8.5–27.1 months) from the start of NEO100 treatment at recurrence. The single-arm, open-label study used a historical benchmark and had no randomized control group. Results differ under the response criteria and estimation method specified in the study protocol. Interim results may change at final analysis.

"We are encouraged by the additional partial response in this update," said Amir F. Heshmatpour, Executive Chairman, President and Chief Executive Officer of NeOnc. "We remain focused on advancing the development of NEO100 for patients with recurrent high-grade glioma."

At the interim analysis, all reported treatment-related adverse events were Grade 1 or 2 and consisted predominantly of local nasal or upper-airway effects. NeOnc reported no treatment-related serious adverse events or discontinuations due to treatment-related adverse events.

About the NEO100-01 Study

NEO100-01 is an open-label, multicenter Phase 1/2a study of intranasal NEO100 in patients with radiographically confirmed progression or recurrence of primary or secondary Grade IV glioma or Grade III astrocytoma harboring an IDH1 mutation. In Phase 2a, 28 patients received the recommended Phase 2 dose of 1,152 mg/day. The efficacy population consisted of 24 patients with IDH1-mutant tumors, including 21 with Grade IV disease. Enrollment is complete.

About NEO100

NEO100 is a highly purified form of perillyl alcohol administered intranasally. Its delivery approach is designed to provide a non-invasive route to the brain. NEO100 remains investigational, and its safety and efficacy have not been established. NEO100 has received Orphan Drug designation from the FDA for the treatment of gliomas.

(Press release, Neonc, NOV 17, 2026, View Source [SID1234674900])